The effect of (±)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze

European Journal of Pharmacology

Volumn 476, Issue 3, 2003, Pages 193-199

  Guscott, Martin R ^a   Clarke, Hannah F ^b   Murray, Fraser ^a   Grimwood, Sarah ^c   Bristow, Linda J ^d   Hutson, Peter H ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b UK   (United Kingdom)

^c PFIZER INC   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

(Rat); CP 101,606; Morris watermaze; NMDA receptor NR2B subunit selective antagonist

Indexed keywords

DIZOCILPINE; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTEIN SUBUNIT; TRAXOPRODIL; WATER; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PIPERIDINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; STATISTICAL SIGNIFICANCE; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MEMORY; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RADIOASSAY; SWIMMING;

ADMINISTRATION, ORAL; ANIMALS; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; INJECTIONS, INTRAPERITONEAL; MALE; MAZE LEARNING; MEMORY; PIPERIDINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SWIMMING;

EID: 0142026804     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02182-4     Document Type: Article

References (39)

1. Blandini F., Nappi G., Greenamyre J.T. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann. Neurol. 49:2001;525-529.
2. Boyce S., Wyatt A., Webb J.K., O'Donnell R., Mason G., Rigby M., Sirinathsinghii D., Hill R.G., Rupniak N.M.J. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology. 38:1999;611-623.
3. Buller A.L., Larson H.C., Schneider B.E., Beaton J.A., Morrisett R.A., Monaghan D.T. The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. J. Neurosci. 14:1994;5471-5484.
4. Castellano C., Cestari V., Ciamei A. NMDA receptors and learning and memory processes. Curr. Drug Targets. 2:2001;273-283.
5. Chatterton J.E., Awobuluyi M., Premkumar L.S., Takahashi H., Talantova M., Shin Y., Cui J., Tu S., Sevarino K.A., Nakanishi N., Tong G., Lipton S.A., Zhang D. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature. 415:2000;793-798.
6. Chazot P.L. CP-101606. Curr. Opin. Investig. Drugs. 1:2000;370-374.
7. Chizh B.A., Headley P.M., Tzschentke T.M. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol. Sci. 22:2001;636-642.
8. Das S., Sasaki Y.F., Rothe T., Premkumar L.S., Takasu M., Crandall J.E., Dikkes P., Conner D.A., Rayudu P.V., Cheung W., Chen H.-S.V., Lipton S.A., Nakanishi N. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature. 393:1998;377-381.
9. Filliat P., Blanchet G. Effects of TCP on spatial memory: comparison with MK-801. Pharmacol. Biochem. Behav. 51:1995;429-434.
10. Gorter J.A., de Bruin J.P.C. Chronic neonatal MK-801 treatment results in an impairment of spatial learning in the adult rat. Brain Res. 580:1992;12-17.
11. 2+ influx into cells stably expressing recombinant human NMDA receptors by ligands acting at distinct recognition sites. J. Neurochem. 6:1996;2589-2595.
12. 3H]ifenprodil binding to recombinant human NR1a/NR2B receptors compared with native receptors in rodent brain membranes. J. Neurochem. 75:2000;2455-2463.
13. Kawabe K., Ichitani Y., Iwasaki T. Effects of intra-hippocampal AP5 treatment on radial-arm maze performance in rats. Brain Res. 781:1998;300-306.
14. Kemp J.A., McKernan R.M. NMDA receptor pathways as drug targets. Nat. Neurosci., Suppl. 5:2002;1039-1042.
15. Kesner R.P., Dakis M. Phencyclidine disrupts acquisition and retention performance within a spatial continuous recognition memory task. Pharmacol. Biochem. Behav. 44:1993;419-424.
16. Koek W., Colpaert F.C. Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects. J. Pharmacol. Exp. Ther. 252:1990;349-357.
17. Kutsuwada T., Kashiwabuchi N., Mori H., Sakimura K., Kushiya E., Araki K., Meguro H., Masaki H., Kumanishi T., Arakawa M. Molecular diversity of the NMDA receptor channel. Nature. 358:1992;36-41.
18. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 268:1994;335-345.
19. Liang K.C., Hon W., Tyan Y.-M., Liao W.-L. Involvement of hippocampal NMDA and AMPA receptors in acquisition, formation and retrieval of spatial memory in the Morris watermaze. Chin. J. Physiol. 37:1994;201-212.
20. Menniti F., Chenard B., Collins M., Ducat M., Shalaby I., Frost White W. CP-101,606, a potent neuroprotectant selective for forebrain neurons. Eur. J. Pharmacol. 331:1997;117-126.
21. Mintz M., Rose I.C., Herberg L.J. The effect of the NMDA receptor antagonist, MK-801, on the course and outcome of kindling. Pharmacol. Biochem. Behav. 35:1990;815-821.
22. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., Seeburg P.H. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science. 256:1992;1217-1221.
23. Newcomer J.W., Krystal J.H. NMDA receptor regulation of memory and behavior in humans. Hippocampus. 11:2001;529-542.
24. Okiyama K., Smith D.H., Frost White W., Richter K., McIntosh T.K. Effects of the novel NMDA antagonists CP-98,113, CP-101,581 and CP-101,606 on cognitive function and regional cerebral oedema following experimental brain injury in the rat. J. Neurotrauma. 14:1997;211-222.
25. Parsons C.G. NMDA receptors as drug targets for drug action in neuropathic pain. Eur. J. Pharmacol. 429:2001;71-78.
26. Pearce J.M., Roberts A.D.L., Good M. Hippocampal lesions disrupt navigation based on cognitive maps but not heading vectors. Nature. 396:1998;75-77.
27. Pitkanen M., Sirvio J., MacDonald E., Niemi S., Ekonsalo T., Riekkinen P. The effects of D-cycloserine and MK-801 on the performance of rats in two spatial learning and memory tasks. Eur. Neuropsychopharmacol. 5:1995;457-463.
28. Priestley T., Laughton P., Myers J., Le Bourdelles B., Kerby J., Whiting P.J. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. Mol. Pharmacol. 48:1995;841-848.
29. Roullet P., Sargolini F., Oloverio A., Mele A. NMDA and AMPA antagonist infusions into the ventral striatum impair different steps of spatial information processing in a non-associative task in mice. J. Neurosci. 21:2001;2143-2149.
30. Schmutz M., Portet C., Jeker A., Klebs K., Vassout A., Allgeier H., Heckendorn R., Fagg G.E., Olpe H.R., van Riezen H. The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn-Schmiedeberg's Arch. Pharmacol. 342:1990;61-66.
31. Shuto S., Yoshii K., Matsuda A. (1S,2R)-1-Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a new class of NMDA-receptor antagonist: molecular design by a novel conformational restriction strategy. Jpn. J. Pharmacol. 85:2001;207-213.
32. Steele R.J., Morris R.G.M. Delay-dependent impairment of a matching-to-place task with chronic and intra-hippocampal infusion of the NMDA-antagonist D-AP5. Hippocampus. 9:1999;118-136.
33. Tang Y.-P., Shimizu E., Dube G.R., Rampon C., Kerchner G.A., Zhou M., Liu G., Tsien J.Z. Genetic enhancement of learning and memory in mice. Nature. 40:1999;163-169.
34. Taniguchi K., Shinjo K., Mizutani M., Shimada K., Ishikawa T., Menniti F.S., Nagahisa A. Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. Br. J. Pharmacol. 122:1997;809-812.
35. Tzschentke T.M. Glutamatergic mechanisms in different disease states: overview and therapeutical implications - an introduction. Amino Acids. 23:2002;147-152.
36. Weber M.L., Taylor C.P., Donevan S.D. CP-101,606, an NR2B selective NMDA receptor antagonist does not block hippocampal LTP. Abstr.-Soc. Neurosci. 25:1999;1485.
37. Wenzel A., Scheurer L., Kunzi R., Fritschy J.M., Mohler H., Benke D. Distribution of NMDA receptor subunit proteins NR2A, 2B, 2C and 2D in rat brain. NeuroReport. 7:1995;45-48.
38. Williams K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol. Pharmacol. 44:1993;851-859.
39. Ylinen A., Pitkanen M., Sirvio J., Hartikainen T., Sivenius J., Koivisto E., Riekkinen P.J. The effects of NMDA receptor antagonists at anticonvulsive doses on the performance of rats in the watermaze task. Eur. J. Pharmacol. 274:1995;159-165.